



Title	CLINICAL SIGNIFICANCE OF HYALURONAN IN PATIENTS WITH INTERSTITIAL PNEUMONIA(本文)
Author(s)	猪腰, 弥生
Citation	
Issue Date	2013-09-25
URL	http://ir.fmu.ac.jp/dspace/handle/123456789/589
Rights	© 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology. This is the peer reviewed version of the following article: [Respirology. 2013 Nov;18(8):1236-43], which has been published in final form at [https://doi.org/10.1111/resp.12144]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
DOI	
Text Version	ETD

This document is downloaded at: 2024-04-19T19:36:12Z



**CLINICAL SIGNIFICANCE OF HYALURONAN IN PATIENTS
WITH INTERSTITIAL PNEUMONIA**

Journal:	<i>Respirology</i>
Manuscript ID:	RES-12-638.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Inokoshi, Yayoi; Fukushima Medical University, Department of Pulmonary Medicine Tanino, Yoshinori; Fukushima Medical University, Department of Pulmonary Medicine wang, xintao; Fukushima Medical University, Department of Pulmonary Medicine Sato, Suguru; Fukushima Medical University, Department of Pulmonary Medicine Fukuhara, Naoko; Fukushima Medical University, Department of Pulmonary Medicine Nikaïdo, Takefumi; Fukushima Medical University, Department of Pulmonary Medicine Fukuhara, Asturo; Fukushima Medical University, Department of Pulmonary Medicine Saito, Junpei; Fukushima Medical University, Department of Pulmonary Medicine Frevort, Charles; University of Washington, Center for Lung Biology Munakata, Mitsuru; Fukushima Medical University, Department of Pulmonary Medicine
Keywords:	Pulmonary fibrosis

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **CLINICAL SIGNIFICANCE OF HYALURONAN IN PATIENTS**
7
8
9 **WITH INTERSTITIAL PNEUMONIA**
10

11
12
13
14
15
16
17 Yayoi Inokoshi, MD ¹⁾, Yoshinori Tanino, MD, PhD¹⁾, Xintao Wang, MD, PhD ¹⁾,
18
19 Suguru Sato, MD, PhD ¹⁾, Naoko Fukuhara, MD ¹⁾, Takefumi Nikaido, MD ¹⁾, Atsuro
20
21 Fukuhara, MD ¹⁾, Junpei Saito, MD, PhD ¹⁾, Charles W Frevert, DVM, ScD²⁾, Mitsuru
22
23
24
25
26 Munakata, MD, PhD ¹⁾
27

28
29
30
31
32 Department of Pulmonary Medicine, Fukushima Medical University School of
33
34
35 Medicine, Fukushima, 960-1295 JAPAN ¹⁾ and Center for Lung Biology, University of
36
37
38 Washington School of Medicine, Seattle, WA 98195 USA ²⁾
39

40
41
42
43 Corresponding Author: Yoshinori Tanino, MD, PhD
44

45
46 Department of Pulmonary Medicine, Fukushima Medical University School of
47
48
49 Medicine
50

51
52 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, JAPAN
53

54
55 Tel: 81-24-547-1360; FAX: 81-24-548-9366; E-mail: ytanino@fmu.ac.jp
56
57
58
59
60

1
2
3
4
5
6 Abstract: 213 words, Text: 2732 words
7

8
9 Authors' contributions: Conceived and designed the experiments: YI, YT, CWF MM.
10

11
12 Collected the samples and patients' information: YI, YT, XW, SS, NF, AF, TN, HY, JS.
13

14
15 Analyzed and interpreted the data: YI, YT, XW, CWF, MM. The guarantor of the
16

17 manuscript: YT.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Summary at a Glance

Although extracellular matrix proteins such as hyaluronan have been thought to be simple “glue” in interstitium of the lung, the results of this study showed that serum hyaluronan is a clinically useful biomarker of interstitial pneumonia, and hyaluronan is involved in the pathogenesis of interstitial pneumonia

ABSTRACT

Background: Hyaluronan is an important constituent of the extracellular matrix in lungs, and growing evidences have shown its important biological properties in lungs.

However, the role of hyaluronan in interstitial pneumonia has not been fully clarified.

Objective: The goal of this study was to clarify the role of hyaluronan in interstitial pneumonia.

Methods: Hyaluronan in serum and bronchoalveolar lavage (BAL) fluid of chronic interstitial pneumonia (CIP) was measured and the correlation with clinical parameters was determined. In addition, the correlation between hyaluronan in serum and clinical parameters was analyzed in patients with acute exacerbation of interstitial pneumonia.

Results: When compared to healthy controls, serum hyaluronan was significantly greater in patients with CIP, and was positively correlated with serum biomarkers of inflammation and fibrosis, such as CRP and surfactant protein-D. In BAL fluid, the amount of hyaluronan was positively correlated with the percentage of inflammatory cells and the amount of CXCL8. When compared to CIP patients, patients with acute exacerbation of interstitial pneumonia had significantly greater amounts of serum hyaluronan and patients with the high serum hyaluronan had the worse 60 day-outcomes.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: This work shows serum hyaluronan is a clinically useful biomarker of interstitial pneumonia, and suggests hyaluronan is involved in the pathogenesis of interstitial pneumonia by recruiting inflammatory cells into the lungs.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: Acute exacerbation, CXCL8, Hyaluronan, Interstitial pneumonia, idiopathic
pulmonary fibrosis

Short title: Hyaluronan in interstitial pneumonia

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABBREVIATIONS

AE = acute exacerbation

BAL = bronchoalveolar lavage

CIP = chronic interstitial pneumonia

CVD-IP = collagen vascular disease-associated interstitial pneumonia

High-HA = a high serum hyaluronan group

HMW = high molecular weight

IPF = idiopathic pulmonary fibrosis

Low-HA = a low serum hyaluronan group

LMW = low molecular weight

TLR = Toll-like receptor

IP = interstitial pneumonia

IP-AE = acute exacerbation of interstitial pneumonia

IIP = idiopathic interstitial pneumonia

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a disease with progressive pulmonary fibrosis that causes chronic and progressive dyspnea and has a poor prognosis.

Histopathologically, IPF presents usual interstitial pneumonia pattern, with deposition of collagen, proteoglycans, and other extracellular matrix proteins. It has been reported inflammatory cytokines, growth factors and Fas/FasL play critical roles in the pathogenesis of IPF [1, 2], although the precise mechanisms have not been clarified.

Hyaluronan, a component of the extracellular matrix is a nonsulfated glycosaminoglycan that accounts for about 70% of the glycosaminoglycans in the lungs. Under physiological conditions, it exists with a high molecular weight (HMW) of more than 10^6 Da and is involved in water regulation and angiogenesis. Unlike HMW hyaluronan, low molecular weight (LMW) hyaluronan of about 2×10^4 Da is a degradation product of HMW hyaluronan, which stimulates the production of inflammatory mediators such as CXCL8 through Toll-like receptor (TLR) 2 and 4 signalling pathways [3].

Although the reports in 1980s which have investigated the role of hyaluronan in diffuse lung diseases suggest hyaluronan is involved in the pathogenesis of interstitial pneumonia (IP) [4, 5], the role of hyaluronan has not been fully elucidated. Today,

1
2
3
4
5
6 with the clear re-classification of idiopathic interstitial pneumonia [6], wide
7
8
9 international recognition of acute exacerbation of interstitial pneumonia (IP-AE) [7],
10
11 and the significant elucidation of the molecular biological properties of hyaluronan, it is
12
13
14
15 time to re-evaluate the role of hyaluronan in IP.

16
17 For this purpose, the levels of hyaluronan in serum and bronchoalveolar lavage
18
19 (BAL) fluid were investigated in patients with IPF, as well as patients with idiopathic
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
interstitial pneumonia other than IPF (IIP) and collagen vascular disease-associated
interstitial pneumonia (CVP-IP). In addition, the level of hyaluronan in serum in
patients with IP-AE was analyzed.

METHODS

Subjects

The patients with chronic interstitial pneumonia (CIP) who had admitted to our hospital between 2006 and 2008 were analyzed. Patients with CIP presented no progression of symptoms such as dyspnea and radiological findings for at least three months. Serological tests, pulmonary function tests, high resolution CT, and BAL were performed for these patients. The diagnosis of idiopathic interstitial pneumonia was made in accordance with the ATS/ERS consensus conference statement [6, 8]. The diagnosis of IPF was made when the condition agreed with the diagnostic criteria for clinical IPF in cases without surgical biopsy. Collagen vascular disease associated-interstitial pneumonia (CVD-IP) was diagnosed when the patient with IP fulfilled the diagnostic criteria of collagen vascular disease, and CIP except IPF and CVD-IP was diagnosed as IIP. These three types of CIP were investigated retrospectively. Twelve healthy volunteers were used as controls. For analysis of IP-AE, the patients with IP-AE who had admitted to our hospital between 2000 and 2008 were analyzed. When fulfilled the following conditions, the diagnosis of IP-AE was made as previously reported [9]: progressive dyspnea within one month; bilateral infiltrates or ground glass opacities; decrease in PaO_2 of ≥ 10 Torr or $\text{PaO}_2/\text{FiO}_2 < 300$;

1
2
3
4
5
6 and ruling out of pneumonia, heart failure, pulmonary thromboembolism, and
7
8 pneumothorax. This study was conducted after receiving the approval of the
9
10 Fukushima Medical University Ethics Committee.
11
12
13

14 15 16 17 **Analysis of clinical parameters and hyaluronan** 18

19
20 Hyaluronan levels in serum from the 12 healthy volunteers and patients with IP, and
21
22 hyaluronan-levels in BAL fluid from patients with IP were analyzed. Associations
23
24 between hyaluronan in serum and blood parameters, pulmonary function tests, and
25
26 inflammatory cell differentiation in BAL fluid were then analyzed. Measurements of
27
28 hyaluronan levels were made using a commercially available kit (Fujirebio, Japan).
29
30
31
32
33
34
35
36

37 38 **Analysis of CXCL8 in BALF** 39

40 To clarify the mechanism for the relationship between hyaluronan and cell
41
42 differentiation in BAL fluid, CXCL8 levels in BAL fluid was investigated. The
43
44 concentration was measured using an ELISA kit (R&D Systems, Minneapolis, MN), as
45
46 previously reported [10].
47
48
49
50
51

52 53 54 55 **Analysis of hyaluronan in patients with acute exacerbation of interstitial** 56 57 58 59 60

1
2
3
4
5
6 **pneumonia**
7

8
9 Hyaluronan levels in serum were measured in patients with IP-AE and compared to
10 patients with clinically stable CIP. In addition, hyaluronan in serum was compared in
11 identical individual during acute exacerbation (AE) with the stable phase. Furthermore,
12 to investigate the association between hyaluronan in serum and prognosis, hyaluronan
13 levels during AE and mortality at 30 and 60 days after the onset of AE were
14 investigated.
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **Statistical analysis**
30

31
32 Data are expressed as means \pm SE, unless otherwise stated. For statistical analysis,
33 Wilcoxon's signed rank test, Fisher's exact test and Pearson's correlation coefficient
34 were used to analyze hyaluronan level in serum for identical individual during AE with
35 the stable phase of IP, prognosis after AE with hyaluronan in serum and correlations
36 between hyaluronan and clinical parameters, respectively. Unless otherwise indicated,
37 Student's *t*-test and analysis of variance with Fisher's PLSD were used for compare two
38 and groups, respectively. $P < 0.05$ was considered to be statistically significant.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS**Subjects and clinical parameters**

Forty nine CIP patients including 24 IPF, 17 IIP, and 8 CVD-IP were analyzed. BAL was performed in 38 out of 49 patients. Surgical lung biopsy was performed in 14 patients (10 IPF, 3 IIP, and 1 CVD-IP). For CVD-IP, the number of patients with rheumatoid arthritis, scleroderma, dermatomyositis and Sjögren's syndrome is 1, 2, 1 and 4 patients, respectively.

In CVD-IP group, significantly more women were included (Table 1), and vital capacity and forced expiratory volume in one second were significantly lower among the three groups. In BAL fluid, the percentage of lymphocytes was significantly higher in IIP and CVD-IP than in IPF (Table 2).

Association between hyaluronan levels and clinical parameters

Hyaluronan in serum was significantly higher in CIP patients than in healthy volunteers (Figure 1), but there was no difference in hyaluronan in serum among three groups. In CIP patients, hyaluronan in BAL fluid (59.5 ± 8.4 ng/ml) had no correlation with hyaluronan in serum, and no difference in serum hyaluronan was seen among the three groups. Hyaluronan in serum had positive correlations with LDH, CRP, ESR,

1
2
3
4
5
6 and SP-D, and a positive trend with SP-A. However, no association was seen with
7
8
9 pulmonary function or cell differentiation in BAL fluid (Table 3). Hyaluronan in BAL
10
11
12 fluid showed negative correlations with total lung capacity and diffusion lung capacity,
13
14 and positive correlations with percentage of neutrophils and lymphocytes in BAL fluid.
15
16
17 In addition, significant positive correlations were seen with inflammatory markers such
18
19
20 as CRP and ESR (Table 4).
21
22
23
24
25

26 **Association between hyaluronan and CXCL8 in BAL Fluid**

27
28
29 Since there was a positive correlation between hyaluronan and percentage of
30
31
32 inflammatory cells such as neutrophils in BAL fluid, the level of CXCL8, a potent
33
34
35 neutrophil chemokine previously known as IL-8, was measured in BAL fluid to identify
36
37
38 potential mechanism whereby hyaluronan might increase neutrophil recruitment into the
39
40
41 lungs. The amount of CXCL8 in BAL fluid was positively correlated with hyaluronan
42
43
44 as well as percentage of neutrophils in BAL fluid (Figure 2).
45
46
47
48
49

50 **Clinical characteristics of patients with acute exacerbation of interstitial** 51 52 **pneumonia**

53
54
55 IP-AE had occurred 24 times in 23 patients in our hospital between 2000 and 2008 (8
56
57
58
59
60

1
2
3
4
5
6 with IPF, 10 with IIP, and 4 with CVD-IP). In IP-AE patients, PaO₂/FiO₂ decreased,
7
8 and KL-6, SP-A and SP-D increased. However, no significant differences were seen
9
10 among three groups (Table 5).
11
12
13
14
15
16
17

18 **Analysis of hyaluronan in serum from patients with acute exacerbation of** 19 20 **interstitial pneumonia** 21

22
23 Hyaluronan in serum was much higher in IP-AE patients than stable CIP patients
24 (Figure 3). We could analyze hyaluronan in serum in 12 patients with IP during AE
25
26 and in the stable phase. In these patients, hyaluronan in serum was significantly higher
27
28 during AE than in the stable phase (Figure 4). We next investigated the association
29
30 between hyaluronan in serum and prognosis. After excluding one patient whose
31
32 clinical outcome was unclear, 22 patients with IP-AE were divided into a high serum
33
34 hyaluronan group (High-HA: n = 11) and a low serum hyaluronan group (Low-HA: n =
35
36 11), according to a median value of 76.2 ng/ml. Although no difference was seen in
37
38 the mortality at 30 days after the onset of AE (4 deaths in High-HA vs. 1 death in
39
40 Low-HA), the mortality at 60 days was significantly worse in High-HA compared with
41
42 in Low-HA (7 deaths in High-HA vs. 1 death in Low-HA).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In this study, we have demonstrated 3 major findings; 1) in CIP patients, hyaluronan in serum was elevated and positively correlated with inflammatory and fibrosis markers; 2) hyaluronan in BAL fluid was negatively correlated with total lung capacity and diffusion lung capacity and positively correlated with the percentage of inflammatory cells and the CXCL8 in BAL fluid; 3) in IP-AE patients, hyaluronan in serum was higher than in the stable phase, and the prognosis was significantly worse in High-HA.

In IP, there is excess deposition of extracellular matrix including proteoglycans in the interstitium. Proteoglycan is glycoprotein with side chains of glycosaminoglycan and basic structure of repeating disaccharide units attached to core protein. For a long time, proteoglycan and glycosaminoglycan have been thought to be simple “glue” that existed in interstitium as extracellular matrix, but in recent years they have attracted attention after being shown to have diverse biological properties [11, 12]. We have recently demonstrated intratracheal instillation of mutant CXCL8 with weak binding affinity for glycosaminoglycan induced more neutrophil recruitment into murine lungs compared with the wild-type CXCL8 [10]. These facts show important roles of chemokines and glycosaminoglycan binding in inflammatory lung diseases.

Hyaluronan is nonsulfated glycosaminoglycan that binds to proteoglycans to form

1
2
3
4
5
6 high molecular weight complexes [13]. Because of its hydrophilic property,
7
8
9 hyaluronan is considered to be important in water regulation and solute transport in the
10
11
12 pulmonary interstitium [14], and to play pivotal roles in lung inflammation and injury [3,
13
14 15]. In patients with IPF, hyaluronan in BAL fluid was reported to be higher in
16
17 progressive phases than in stable phases, and positively correlated with the number of
18
19 inflammatory cells in BAL fluid, and expression of hyaluronan is seen in fibroblastic
20
21 foci [5, 16]. In bleomycin-induced lung fibrosis, elevated hyaluronan in BAL fluid
22
23 positively correlated with inflammatory cells in BAL fluid and associated with the
24
25 degree of alveolitis in the fibrotic lungs [17], and overexpression of hyaluronan by
26
27 myofibroblasts produced an aggressive phenotype leading to severe lung fibrosis [18]
28
29
30
31
32
33
34

35 In recent years, idiopathic interstitial pneumonia has been re-classified into seven
36
37 distinct groups based on the classifications of the AECC statement [6], KL-6, SP-D, and
38
39 other lung fibrotic markers have been used in regular clinical settings [19-21], and the
40
41 occurrence of AE in the course of CIP has also come to be widely recognized [22, 23].
42
43
44 Furthermore, the molecular biological properties of hyaluronan have also become
45
46 clearer. We therefore re-investigated the role of hyaluronan on the pathogenesis of IP.
47
48
49
50
51

52 In this study, hyaluronan in BAL fluid was positively correlated with the percentage
53
54 of inflammatory cells in BAL fluid, and hyaluronan in serum was significantly higher in
55
56
57
58
59
60

1
2
3
4
5
6 CIP patients and positively correlated with inflammatory and fibrosis markers. These
7
8
9 facts suggest hyaluronan could be useful as a clinical marker of CIP.

10
11
12 Hyaluronan is synthesized mainly by fibroblasts in the lungs, and growth factors such
13
14 as TGF- β make a major contribution to its synthesis [24]. Hyaluronan synthase was
15
16 recently identified, and in humans it exists in three isoforms [25]. In healthy lungs,
17
18 hyaluronan moves from the lungs to the systemic circulation via lymphatics, and it is
19
20 finally metabolised and excreted in the liver [26]. The mechanism of increased level
21
22 of hyaluronan in IP is not clear, but increased production or decreased metabolism of
23
24 hyaluronan in the lungs may be involved. In addition, because hyaluronan is degraded
25
26 by reactive oxygen species from HMW into LMW molecules [27], HMW hyaluronan is
27
28 degraded into LMW hyaluronan in the lungs of IP in which reactive oxygen species are
29
30 increased [28]. In fact, recent reports have shown LMW hyaluronan exists as well as
31
32 HMW hyaluronan in BAL fluid of patients with IPF [29]. Among hyaluronidases,
33
34 enzymes which degrade HMW hyaluronan, hyaluronidase-2 is shown to be mainly
35
36 involved in the production of LMW hyaluronan [30], and increased expression of
37
38 hyaluronan synthases by TGF- β in lung fibroblasts may also be related to the increased
39
40 production of hyaluronan in IP lungs. In addition, in bleomycin-induced lung fibrosis,
41
42 LMW hyaluronan inhibits apoptosis of lung epithelial cells via activation of
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 TLR-dependent NF- κ B activation, while it initiates inflammatory responses via TLR2
7
8
9 and 4. Furthermore, it has been reported overexpression of HMW hyaluronan in the
10
11 lungs suppressed acute lung injury [3]. These recent reports also show the importance
12
13 of hyaluronan in lung inflammation and repair, while precise elucidation of the
14
15 hyaluronan metabolic pathway in the body is complicated.
16
17
18
19

20 To further investigate the role of hyaluronan in IP, we also analyzed the level of
21
22 CXCL8. It has recently been demonstrated increased percentage of neutrophil in BAL
23
24 fluid is a predictor of early mortality in patients with IPF [31] as well as IP associated
25
26 with systemic sclerosis [32, 33], and neutrophils are considered to be involved in the
27
28 pathogenesis of IP. CXCL8 in BAL fluid showed a positive correlation with the
29
30 percentage of neutrophils as well as hyaluronan in BAL fluid, showing, in IP,
31
32 hyaluronan is involved in neutrophil migration into the lungs via CXCL8. In fact,
33
34 LMW hyaluronan promotes expression of inflammatory cytokines and chemokines in
35
36 alveolar macrophages via TLR activation. From previous findings and the results of
37
38 the present study, neutrophil migration into IP lungs is at least in part, dependent of the
39
40 increased production of CXCL8 from alveolar macrophages by stimulation of TLRs
41
42 with hyaluronan which is produced from fibroblasts and other cells [3].
43
44
45
46
47
48
49
50
51
52
53
54

55 In recent years, IP-AE, in which respiratory failure progresses rapidly together with
56
57
58
59
60

1
2
3
4
5
6 the appearance of new opacities in the bilateral lungs during the course of CIP, has
7
8
9 widely recognised. Initially, AE was reported only in patients with IPF, but recent
10
11
12 reports have shown AE also occur in patients with non-IPF [1, 34]. The cause of AE is
13
14
15 unknown, but once it occurs, the prognosis is poor, with a mortality rate of more than
16
17
18 80%, making it important as a prognostic factor of IP [35]. In the present study,
19
20
21 hyaluronan in serum was higher during AE than in the stable phase, and the prognosis
22
23
24 of patients in High-HA was significant worse than patients in Low-HA, showing
25
26
27 hyaluronan in serum could be a useful predictive biomarker of prognosis in patients
28
29
30 with IP-AE.

31
32 Our study has several limitations. First, the classification of IP may not be sufficient,
33
34
35 because the pathological evaluation of lung tissues obtained by surgical lung biopsy was
36
37
38 performed only in the limited patients. There is a possibility that some patients with
39
40
41 IPF who had atypical clinical and/or radiological findings are include in the IIP group,
42
43
44 because we can not distinguish such IPF patients with IIP other than IPF by the
45
46
47 diagnostic criteria of ATS/ERS consensus conference statement. Second, for the
48
49
50 analysis of some data, we put all patients in the three groups together. Because the
51
52
53 pathogenesis of IPF is considered to be different from other types of IP especially in
54
55
56 terms of fibrotic process, it may be better to get the results and analyze the data in each
57
58
59
60

1
2
3
4
5
6 group separately. However, the role of HA, particularly on pulmonary inflammation (e.
7
8
9 g., neutrophil migration) could not be different between IPF and other types of IP.
10
11 Furthermore, recent evidence suggests that inflammation is involved in the pathogenesis
12
13 of not only IP other than IPF but also IPF. For example, increased percentage of
14
15 neutrophil in BALF was shown as a predictor of mortality in patients with IPF [31], and
16
17 Reilkoff RA *et al.* have recently shown that regulatory T cells are associated with
18
19 progressive IPF [36]. However, the limited number of patients and difficulty of
20
21 accurate diagnosis for some patients without surgical lung biopsy made the separate
22
23 analysis of each group difficult in the present study, further analysis for more patients
24
25 with interstitial pneumonia with a precise definition is necessary to resolve these
26
27 limitations. The diagnostic criteria of the recent official ATS/ERS/JRS/ALAT
28
29 statement for IPF could be helpful [37]. Third, we had not analyzed the molecular size
30
31 of hyaluronan in the present study. However, LMW hyaluronan is supposed to be
32
33 increased in biological samples from our patients, because El-Chemaly S *et al.* have
34
35 recently shown that LMW hyaluronan is increased in BALF from patients with IPF
36
37 [29].
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 In summary, hyaluronan in serum is a clinically useful biomarker in IP including AE,
53
54 and hyaluronan is involved in the pathogenesis of IP by recruiting inflammatory cells
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

into the lungs.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENT

This study was partly supported by a grant to the Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare, Japan.

REFERENCES

1. Kuwano K, Miyazaki H, Hagimoto N, *et al.* The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. *Am. J. Respir. Cell. Mol. Biol.* 1999; **20**:53-60.
2. Hagimoto N, Kuwano K, Inoshima I, *et al.* TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. *J. Immunol.* 2002; **168**:6470-8.
3. Jiang D, Liang J, Fan J, *et al.* Regulation of lung injury and repair by Toll-like receptors and hyaluronan. *Nat. Med.* 2005; **11**:1173-9.
4. Milman N, Kristensen MS, Bentsen K, *et al.* Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. *Sarcoidosis* 1995; **12**:38-41.
5. Bjermer L, Lundgren R, Hallgren R. Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. *Thorax* 1989; **44**:126-131.
6. Demedts M and U Costabel. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Eur. Respir. J.* 2002; **19**:794-6.
7. Collard HR, Moore BB, Flaherty KR, *et al.* Idiopathic Pulmonary Fibrosis

- 1
2
3
4
5
6 Clinical Research Network Investigators. Acute exacerbations of idiopathic
7
8
9 pulmonary fibrosis. *Am. J. Respir. Crit. Care. Med.* 2007; **176**:636–643.
10
11
12 8. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and
13
14 treatment. International consensus statement. American Thoracic Society (ATS)
15
16 and the European Respiratory Society (ERS). *Am. J. Respir. Crit. Care. Med.*
17
18 2000; **161**:646-664.
19
20
21
22
23 9. Park IN, Kim DS, Shim TS, *et al.* Acute exacerbation of interstitial pneumonia
24
25 other than idiopathic pulmonary fibrosis. *Chest* 2007; **132**:214-220.
26
27
28
29 10. Tanino Y, Coombe DR, Gill SE, *et al.* Kinetics of chemokine -glycosaminoglycan
30
31 interactions control neutrophil migration into the airspaces of the lungs. *J.*
32
33 *Immunol.* 2010; **184**:2677-2685.
34
35
36
37
38 11. Garantziotis, S, Zudaire E, Trempus CS, *et al.* Serum inter-alpha-trypsin inhibitor
39
40 and matrix hyaluronan promote angiogenesis in fibrotic lung injury. *Am. J. Respir.*
41
42 *Crit. Care. Med.* 2008; **178**:939-47.
43
44
45
46 12. Tanino Y, Chang MY, Wang W, *et al.* Syndecan-4 Regulates Early Neutrophil
47
48 Migration and Pulmonary Inflammation in Response to Lipopolysaccharide. *Am.*
49
50 *J. Respir. Cell. Mol. Biol.* 2012; **47**:196-202.
51
52
53
54
55 13. Gill S, Wight TN, Frevert CW. Proteoglycans: key regulators of pulmonary
56
57
58
59
60

- 1
2
3
4
5
6 inflammation and the innate immune response to lung infection. *Anat. Rec.* 2010;
7
8
9 293:968-981.
- 10
11
12 14. Allen SJ, Gunnar Sedin E, *et al.* Lung hyaluronan during development: a
13
14 quantitative and morphological study. *Am. J. Physiol.* 1991; 260:1449-1454.
15
16
17 15. Teder P, Vandivier RW, Jiang D, *et al.* Resolution of lung inflammation by CD44.
18
19
20 *Science* 2002; 296:155-8.
21
22
23 16. Bensadoun ES, Burke AK, Hogg JC, *et al.* Proteoglycan deposition in pulmonary
24
25 fibrosis. *Am. J. Respir. Crit. Care. Med.* 1996; 154:1819-1828.
26
27
28
29 17. Zhao HW, Lü CJ, Yu RJ, *et al.* An increase in hyaluronan by lung fibroblasts: a
30
31
32 biomarker for intensity and activity of interstitial pulmonary fibrosis? *Respirology*
33
34
35 1999; 4:131-138.
36
37
38 18. Li Y, Jiang D, Liang J, *et al.* Severe lung fibrosis requires an invasive fibroblast
39
40
41 phenotype regulated by hyaluronan and CD44. *J. Exp. Med.* 2011; 208:1459-71.
42
43
44 19. Kinder BW, Brown KK, McCormack FX, *et al.* Serum surfactant protein-A is a
45
46
47 strong predictor of early mortality in idiopathic pulmonary fibrosis. *Chest* 2009;
48
49
50 135:1557-1563.
51
52
53 20. Greene KE, King TE Jr, Kuroki Y, *et al.* Serum surfactant proteins-A and -D as
54
55
56 biomarkers in idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2002; 19:439-446.
57
58
59
60

- 1
2
3
4
5
6 21. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of
7
8 interstitial pneumonitis. *J. Med. Invest.* 1999; 46:151-8.
9
10
11 22. Rice AJ, Wells AU, Bouros D, *et al.* Terminal diffuse alveolar damage in relation
12
13 to interstitial pneumonias. An autopsy study. *Am. J. Clin. Pathol.* 2003;
14
15 119:709-714.
16
17
18 23. Ambrosini V, Cancellieri A, Chilosi M, *et al.* Acute exacerbation of idiopathic
19
20 pulmonary fibrosis: report of a series. *Eur. Respir. J.* 2003; 22:821-826.
21
22
23 24. Heldin P, Laurent TC, Heldin CH. Effect of growth factors on hyaluronan
24
25 synthesis in cultured human fibroblasts. *Biochem. J.* 1989; 258:919-922.
26
27
28 25. Itano N, Sawai T, Yoshida M, *et al.* Three isoforms of mammalian hyaluronan
29
30 synthases have distinct enzymatic properties. *J. Biol. Chem.* 1999;
31
32 274:25085-25092.
33
34
35 26. Laurent TC, Fraser JR. Hyaluronan. *FASEB J.* 1992; 6:2397-2404.
36
37
38 27. Eberlein M, Scheibner KA, Black KE, *et al.* Anti-oxidant inhibition of hyaluronan
39
40 fragment-induced inflammatory gene expression. *J. Inflamm. (Lond)* 2008; 5:20.
41
42
43 28. Demedts M, Behr J, Buhl R, *et al.* IFIGENIA Study Group. High-dose
44
45 acetylcysteine in idiopathic pulmonary fibrosis. *N. Engl. J. Med.* 2005;
46
47 353:2229-2242.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 29. El-Chemaly S, Malide D, Zudaire E, *et al.* Abnormal lymphangiogenesis in
7
8 idiopathic pulmonary fibrosis with insights into cellular and molecular
9
10 mechanisms. *Proc. Natl. Acad. Sci. USA* 2009; **106**:3958-3963.
11
12
13
14 30. Lepperdinger G, Mullegger J, Kreil G. Hyal2--less active, but more versatile?
15
16
17 *Matrix Biol.* 2001; **20**:509-514.
18
19
20 31. Kinder BW, Brown KK, Schwarz MI, *et al.* Baseline BAL neutrophilia predicts
21
22
23 early mortality in idiopathic pulmonary fibrosis. *Chest* 2008; **133**:226-232.
24
25
26 32. Behr J, Vogelmeier C, Beinert T, *et al.* Bronchoalveolar lavage for evaluation and
27
28
29 management of scleroderma disease of the lung. *Am. J. Respir. Crit. Care. Med.*
30
31
32 1996; **154**:400-6.
33
34
35 33. White B, Moore WC, Wigley FM, *et al.* Cyclophosphamide is associated with
36
37
38 pulmonary function and survival benefit in patients with scleroderma and
39
40
41 alveolitis. *Ann. Inter. Med.* 2000; **132**:947-954.
42
43
44 34. Churg A, Müller NL, Silva CI, *et al.* Acute exacerbation (acute lung injury of
45
46
47 unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. *Am. J.*
48
49
50 *Surg. Pathol.* 2007; **31**:277-284.
51
52
53 35. Kim DS, Park JH, Park BK, *et al.* Acute exacerbation of idiopathic pulmonary
54
55
56 fibrosis: frequency and clinical features. *Eur. Respir. J.* 2006; **27**:143-150.
57
58
59
60

- 1
2
3
4
5
6 36. Reilkoff RA, Peng H, Lynne A, *et al.* Semaphorin 7a(+) regulatory T cells are
7
8 associated with progressive idiopathic pulmonary fibrosis and are implicated in
9
10 transforming growth factor- β 1-induced pulmonary fibrosis. *Am. J. Respir. Crit.*
11
12 *Care. Med.* 2013; **187**:180-8.
13
14
15
16
17 37. Raghu G, Collard HR, Egan JJ, *et al.* An official ATS/ERS/JRS/ALAT statement:
18
19 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
20
21 management. *Am. J. Respir. Crit. Care. Med.* 2011; **183**:788-824.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: The Serum Level of Hyaluronan in healthy volunteers (HV) and chronic interstitial pneumonia (CIP). The level of hyaluronan in serum was significantly higher in patients with CIP than in HV. * $p < 0.05$ vs. HV.

Figure 2: Correlation of CXCL8 with Neutrophil Percent and Hyaluronan in bronchoalveolar lavage fluid (BALF). The concentration of CXCL8 in BALF from patients with interstitial pneumonia had positive correlation with neutrophil percent (A) and hyaluronan (B) in BALF.

Figure 3: The Serum Levels of Hyaluronan in Patients with Stable and Acute Exacerbation of Interstitial Pneumonia. The level of hyaluronan in serum was significantly higher in patients with acute exacerbation of IP than in IP-stable. IP-stable = patients with stable IP; IP-AE = patients with acute exacerbation of IP. Values are the mean + SEM. * $p < 0.05$ vs. IP-stable.

Figure 4: Evolution of Serum hyaluronan (HA) levels in Patients with Interstitial Pneumonia before and upon Acute Exacerbation (n = 12). Serum HA upon acute

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

exacerbation is significantly higher than before acute exacerbation.

Table 1. Clinical Characteristics of Patients with CIP

	Total	IPF	IIP	CVD-IP	P value
Subjects n	49	24	17	8	
Age yrs	64.0 ± 1.3	64.6 ± 1.7	63.5 ± 2.5	63.1 ± 3.0	NS
Gender M/F	36/13	22/2	12/5	2/6*	P < 0.05
PaO ₂ mmHg	79.1 ± 2.3	81.5 ± 3.5	74.3 ± 4.1	81.4 ± 2.9	NS
WBC /μL	7821 ± 376	7804 ± 426	8281 ± 650	6950 ± 1385	NS
CRP mg/dl	0.8 ± 0.2	0.5 ± 0.2	1.1 ± 0.6	1.3 ± 0.6	NS
ESR mm/hr	35 ± 4	31 ± 4	34 ± 6	51 ± 13	NS
LDH U/ml	243 ± 12	238 ± 10	256 ± 29	234 ± 37	NS
KL-6 U/ml	1438 ± 142	1529 ± 228	1444 ± 241	1153 ± 176	NS
SP-A ng/ml	113.9 ± 12.4	126.5 ± 19.1	109.4 ± 22.4	83.8 ± 15.2	NS
SP-D ng/ml	232.0 ± 21.1	249.3 ± 31.2	226.7 ± 39.5	190.1 ± 36.8	NS

CIP = chronic interstitial pneumonia, CRP = C reactive protein, CVD-IP = collagen vascular disease associated with interstitial pneumonia, ESR = erythrocyte sedimentation rate, IPF: idiopathic pulmonary fibrosis, IIP: idiopathic interstitial pneumonia other than IPF, KL-6 = Krebs von den lungen-6, SP-A = surfactant protein-A, SP-D = surfactant protein-D. Values are the mean ± SEM. * P < 0.05 vs IPF group
81x60mm (300 x 300 DPI)

Table 2. PFT and BAL Analysis of Patients with CIP

	Total (n = 49)	IPF (n = 24)	IIP (n = 17)	CVD-IP (n = 8)	P value
VC L	2.3 ± 0.1	2.5 ± 0.2	2.4 ± 0.2	1.7 ± 0.1 ^{††}	P < 0.05
VC % pred	76.1 ± 2.7	77.0 ± 4.4	80.5 ± 1.7	66.1 ± 6.4	NS
FEV ₁ L	1.93 ± 0.09	2.07 ± 0.13	1.93 ± 0.12	1.35 ± 0.11 ^{††}	P < 0.05
FEV ₁ /FVC %	85.8 ± 1.3	86.6 ± 1.6	87.7 ± 2.3	78.1 ± 3.4	NS
TLC % pred	79.3 ± 2.7	80.4 ± 3.8	84.8 ± 4.3	69.4 ± 6.4	NS
DL _{CO} % pred	55.8 ± 3.5	54.7 ± 5.2	58.6 ± 6.7	50.4 ± 6.5	NS
DL _{N₂} % pred	77.7 ± 3.7	72.9 ± 4.6	80.4 ± 8.5	83.0 ± 7.8	NS
Total Cell Count (x 10 ⁴ /ml BALF)	33.2 ± 9.1	27.5 ± 4.5	47.7 ± 21.4	15.2 ± 3.6	NS
AM %	67.7 ± 3.2	77.4 ± 2.5	61.6 ± 6.0	63.5 ± 10.3	NS
Lym %	17.9 ± 2.1	10.6 ± 1.6	19.8 ± 3.7*	24.9 ± 4.8*	P < 0.05
Neu %	11.2 ± 2.6	8.1 ± 1.7	15.9 ± 6.5	9.5 ± 5.0	NS
Eos %	3.7 ± 0.8	5.1 ± 1.6	3.2 ± 1.0	2.2 ± 0.7	NS

Patients with CVD-IP include rheumatoid arthritis (n = 1), scleroderma (n = 2), dermatomyositis (n = 1) and primary Sjögren syndrome (n = 4). AM = alveolar macrophages, BALF = bronchoalveolar lavage fluid, CIP = chronic interstitial pneumonia, CVD-IP = collagen vascular disease associated interstitial pneumonia, DLCO = diffusing capacity for carbon monoxide, Eos = eosinophils, FEV₁ = Forced expiratory volume in one second, FVC = forced vital capacity, IIP = idiopathic interstitial pneumonia other than IPF, IPF = idiopathic pulmonary fibrosis, Lym = lymphocytes; Neu = neutrophils, PFT = pulmonary function test, TLC = total lung capacity. Values are the mean ± SEM. * P < 0.05 vs IIP group, † P < 0.05 vs IPF group
81x60mm (300 x 300 DPI)

Table 3. Correlation Analysis between Serum Hyaluronan and Clinical Parameters in Patients with CIP

	Correlation coefficients	P value
KL-6 U/ml	0.099	0.905
SP-A ng/ml	0.314	0.055
SP-D ng/ml	0.405	0.011
LDH U/ml	0.658	<0.001
CRP mg/dl	0.502	0.001
ESR mm/hr	0.406	0.013
PaO ₂ mmHg	0.007	0.969
VC % pred	0.273	0.102
FEV ₁ L	0.212	0.208
TLC % pred	0.224	0.235
DL _{co} % pred	0.102	0.580
Total Cell Count x10 ⁴ /ml BALF	0.103	0.625
Lym in BALF %	0.091	0.619
Neu in BALF %	0.211	0.245

CIP = chronic interstitial pneumonia, BALF = bronchoalveolar lavage fluid, CRP = C reactive protein, DLCO = diffusing capacity for carbon monoxide, ESR = erythrocyte sedimentation rate, Lym = lymphocytes; Neu = neutrophils, KL-6 = Krebs von den lungen-6, SP-A = surfactant protein-A, SP-D = surfactant protein-D, VC = vital capacity.

81x60mm (300 x 300 DPI)

Table 4. Correlation Analysis between Hyaluronan in BALF and Clinical Parameters in Patients with CIP

	Correlation coefficients	P value
KL-6 U/ml	0.128	0.457
SP-A ng/ml	0.002	0.993
SP-D ng/ml	0.016	0.924
LDH U/ml	-0.172	0.316
CRP mg/dl	0.424	0.011
ESR mm/hr	0.366	0.033
PaO ₂ mmHg	0.175	0.339
VC % pred	-0.328	0.055
FEV ₁ L	-0.255	0.140
TLC % pred	-0.448	0.019
DL _{co} % pred	-0.048	0.026
Total Cell Count x10 ⁴ /ml BALF	0.099	0.602
Lym in BALF %	0.347	0.044
Neu in BALF %	0.483	0.004

CIP = chronic interstitial pneumonia, BALF = bronchoalveolar lavage fluid, CRP = C reactive protein, DLCO = diffusing capacity for carbon monoxide, FEV₁ = forced expiratory volume in one second, ESR = erythrocyte sedimentation rate, Lym = lymphocytes; Neu = neutrophils, KL-6 = Krebs von den lungen-6, SP-A = surfactant protein-A, SP-D = surfactant protein-D, YLC = total lung capacity, VC = vital capacity.
81x60mm (300 x 300 DPI)

Table 5. Clinical Data of Patients with Acute Exacerbation of Interstitial Pneumonia

	Total	IPF	IIP	CVD-IP	P value
Subjects n	22	8	10	4	
Cases n	23	9 (39%)	10 (43%)	4 (17%)	
Age yrs	65.3 ± 2.0	64.2 ± 4.0	70.2 ± 1.6	55.8 ± 2.6*	P < 0.05
Gender M/F	14/8	6/2	7/3	1/3†	P < 0.05
PaO ₂ /FIO ₂	218.7 ± 19.5	176.9 ± 27.7	257.4 ± 28.8	205.3 ± 48.5	NS
WBC /μ L	10977 ± 898	9863 ± 890	10970 ± 1541	13225 ± 2641	NS
CRP mg/dl	5.8 ± 1.2	5.6 ± 2.0	7.3 ± 2.1	2.5 ± 1.7	NS
ESR mm/hr	28 ± 8	20 ± 13	31 ± 12	33 ± 25	NS
LDH U/ml	416 ± 28	391 ± 47	388 ± 27	536 ± 89	NS
KL-6 U/ml	1668 ± 251	1907 ± 334	1548 ± 447	1554 ± 519	NS
SP-A ng/ml	208.4 ± 102.2	131.3 ± 33.4	72.6 ± 4.8	421.5 ± 234.5	NS
SP-D ng/ml	327.2 ± 54.9	471.8 ± 111.0	279.4 ± 70.9	193.8 ± 68.3	NS

Patients with CVD-IP include dermatomyositis (n = 2), polymyositis (n = 1), Sjögren syndrome (n = 2), scleroderma (n = 1). One dermatomyositis patient is complicated with Sjögren syndrome. CVD-IP = collagen vascular disease associated interstitial pneumonia, ESR = erythrocyte sedimentation rate, IIP = idiopathic interstitial pneumonia other than IPF, IPF = idiopathic pulmonary fibrosis, KL-6 = Krebs von den lungen-6, SP-A = surfactant protein-A, SP-D = surfactant protein-D. Values are the mean ± SEM. * P < 0.05 vs IIP group, † P < 0.05 vs IPF group

81x60mm (300 x 300 DPI)




Figure 1: The Serum Level of Hyaluronan in healthy volunteers (HV) and chronic interstitial pneumonia (CIP). The level of hyaluronan in serum was significantly higher in patients with CIP than in HV. * $p < 0.05$ vs. HV.
81x60mm (300 x 300 DPI)




Figure 2: Correlation of CXCL8 with Neutrophil Percent and Hyaluronan in bronchoalveolar lavage fluid (BALF). The concentration of CXCL8 in BALF from patients with interstitial pneumonia had positive correlation with neutrophil percent (A) and hyaluronan (B) in BALF.
81x60mm (300 x 300 DPI)




Figure 3: The Serum Levels of Hyaluronan in Patients with Stable and Acute Exacerbation of Interstitial Pneumonia. The level of hyaluronan in serum was significantly higher in patients with acute exacerbation of IP than in IP-stable. IP-stable = patients with stable IP; IP-AE = patients with acute exacerbation of IP. Values are the mean + SEM. * $p < 0.05$ vs. IP-stable.
81x60mm (300 x 300 DPI)




Figure 4: Evolution of Serum hyaluronan (HA) levels in Patients with Interstitial Pneumonia before and upon Acute Exacerbation (n = 12). Serum HA upon acute exacerbation is significantly higher than before acute exacerbation.
81x60mm (300 x 300 DPI)